Arbutus Biopharma has patented a method to reduce infusion reactions during intravenous administration of lipid formulated therapeutic agents in mammals. The method involves administering a nonsteroidal anti-inflammatory drug along with the therapeutic agent, specifically using ketorolac with lipid nanoparticles containing nucleic acids, polypeptides, or organic compounds. GlobalData’s report on Arbutus Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Arbutus Biopharma Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Arbutus Biopharma, Peptide pharmacophores was a key innovation area identified from patents. Arbutus Biopharma's grant share as of April 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Method of treating infusion reaction with lipid formulated therapeutic agent

Source: United States Patent and Trademark Office (USPTO). Credit: Arbutus Biopharma Corp

A recently granted patent (Publication Number: US11904052B2) discloses a method for ameliorating infusion reactions associated with the intravenous administration of lipid-formulated therapeutic agents in mammals. The method involves administering a nonsteroidal anti-inflammatory drug (NSAID), specifically ketorolac, in combination with the lipid-formulated therapeutic agent. The lipid formulation includes a nucleic acid, polypeptide, or organic compound formulated in a lipid nanoparticle (LNP) containing a cationic lipid and a non-cationic lipid. The infusion reactions targeted by this method include hypertension, hypotension, and an increase in plasma thromboxane B2 levels.

The method outlined in the patent involves administering the NSAID, ketorolac, within 2 hours prior to the intravenous administration of the lipid-formulated therapeutic agent. The dosage of ketorolac ranges from 15 mg to 60 mg, with a preferred range of 30 mg to 60 mg. The lipid-formulated therapeutic agent can be an antibody, siRNA, or mRNA, with specific emphasis on siRNA and mRNA. Additionally, the method allows for the administration of additional therapeutic agents, such as dexamethasone, to further enhance the amelioration of infusion reactions. The NSAID can be administered parenterally, intravenously, intramuscularly, or subcutaneously, providing flexibility in the delivery of the treatment regimen.

To know more about GlobalData’s detailed insights on Arbutus Biopharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies